Q-omics provides the consensus-scored FAM186B profile across patient tissues and cancer cell-line models. FAM186B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM186B is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, FAM186B RNA expression shows 19,501 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight HNSC, THCA, and LAML as cancer lineages where FAM186B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM186B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM186B survival associations across molecular data types. FAM186B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM186B RNA expression–survival associations across cancer types. High FAM186B expression shows unfavorable associations in THCA, LGG and BLCA, but favorable associations in HNSC, SCLC and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM186B RNA expression.
This table summarizes FAM186B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM186B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM186B shows lower tumor expression in THCA and BRCA and higher tumor expression in COAD, KICH, LUSC and LUAD. The THCA box plot shows higher FAM186B RNA expression in normal versus tumor tissue (log2 FC = −0.425, t-test p < 0.001).
This table shows molecular features associated with FAM186B in patient tissues and cancer cell lines. In patient samples, FAM186B shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM186B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
